Objective 6–12-week-old healthy infants were randomly assigned to receive three oral doses of RotaTeq or placebo in the Rotavirus Efficacy and Safety Trial (REST). To determine if RotaTeq remains efficacious beyond 2 years after vaccination, approximately 21 000 REST infants in the Finnish safety cohort were followed for healthcare encounters, defined as rotavirus gastroenteritis (RVGE)-associated hospitalisations and/or emergency department visits, in the Finnish Extension Study (FES) for up to 3.1 years.
Methods The infants were contacted every 12 weeks to determine whether they had any RVGE-related healthcare encounters. RVGE was defined as forceful vomiting and/or three or more watery or looser-than-normal stools within a 24-h period and detection of rotavirus antigen by ELISA, plaque assay and PCR assays (P and G types). Infants with RVGE, who received three vaccine doses, were included in the analysis; follow-up started 14 days after dose 3.
Results The maximum follow-up time in FES was 3.1 years (1126 days). Overall, pentavalent rotavirus vaccine reduced the rate of RVGE-associated healthcare encounters, regardless of rotavirus serotype, by 94% (95% CI 91.3 to 95.9), demonstrating an overall reduction of healthcare-resource utilisation similar to that of REST (95% CI 91.5 to 96.5). See table for further details.
Conclusion RotaTeq significantly reduced RVGE-associated hospitalisations and emergency department visits for up to 3.1 years of follow-up. The results of FES are consistent with the results of REST and confirm that the efficacy of RotaTeq remains consistent beyond 2 years and up to 3.1 years.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.